Cargando…

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Biomarkers are quantifiable characteristics of biological processes. In Mycobacterium tuberculosis, common biomarkers used in clinical drug development are colony forming unit (CFU) and time-to-positivity (TTP) from sputum samples. This analysis aimed to develop a combined quantitative tuberculosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayoun Alsoud, Rami, Svensson, Robin J., Svensson, Elin M., Gillespie, Stephen H., Boeree, Martin J., Diacon, Andreas H., Dawson, Rodney, Aarnoutse, Rob E., Simonsson, Ulrika S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043246/ https://www.ncbi.nlm.nih.gov/pubmed/36998606 http://dx.doi.org/10.3389/fphar.2023.1067295

Ejemplares similares

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
por: Mockeliunas, Laurynas, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
por: Mudde, Saskia E, et al.
Publicado: (2021)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
por: Wicha, Sebastian G., et al.
Publicado: (2018)

Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin‐Treated Pulmonary Tuberculosis
por: Svensson, RJ, et al.
Publicado: (2016)

Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
por: Svensson, Robin J., et al.
Publicado: (2017)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
por: Faraj, Alan, et al.
Publicado: (2020)

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

Improving treatment outcome assessment in a mouse tuberculosis model
por: Mourik, Bas C., et al.
Publicado: (2018)

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
por: Boeree, Martin J, et al.
Publicado: (2017)

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
por: Aguilar Diaz, Jessica M, et al.
Publicado: (2023)

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Residual Spinal Cord Compression Following Hemilaminectomy and Mini-Hemilaminectomy in Dogs: A Prospective Randomized Study
por: Svensson, Gustaf, et al.
Publicado: (2017)

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection
por: Rullas, Joaquín, et al.
Publicado: (2015)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
por: Keutzer, Lina, et al.
Publicado: (2020)

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study
por: Bryant, Josephine M, et al.
Publicado: (2013)

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
por: van Wijk, Rob C., et al.
Publicado: (2023)

Drug Susceptibility of Mycobacterium tuberculosis Beijing Genotype and Association with MDR TB
por: de Steenwinkel, Jurriaan E.M., et al.
Publicado: (2012)

Clofazimine for the treatment of tuberculosis
por: Stadler, Jacob A. M., et al.
Publicado: (2023)

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
por: Tweed, Conor D., et al.
Publicado: (2018)

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
por: van Wijk, Rob C., et al.
Publicado: (2023)

A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
por: Clewe, Oskar, et al.
Publicado: (2016)

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
por: Tweed, Conor Duncan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3r0nfmr9vo12r81bpkrh7v29t3